声明
CONTENTS
摘要
English Abstract
ABBREVIATIONS
CHAPTER 1 Introduction And Study Objectives
1.1:Introduction
1.2:Study Objective
Chapter 2 Background and Literature Review
2.1:Myocardial infarction
History and epidemiology
Risk factors
Definitions
Pathophysiology
The vulnerable plaque
Factors Influencing plaque rupture
Thrombus formation
Infarct progression
Etiology
Clinical features
Symptoms and sign
Investigation
Diagnostic criteria
Physical examination
Electrocardiogram
Cardiae markers
Angiography
Histopathology
Treatment
General principles
Patient-dependent initial measures
Emergency services
Initial diagnostic approach
Relief of angina
Nitrates
Beta-blockers
Oxygen therapy
Analgesics
Anti-platelet drugs
Aspirin
P2Y12 inhibitors
Glycoprotein Ⅱb/Ⅲa inhibitors
Anticoagulants
Reperfusion
Rehabilitation
Prevention
Lifestyle
Medication
Chapter 3 Percutaneous Coronary Intervention
History of PCI
Medical uses
Adverse events
Proeedure
Types of stents
Thrombus aspiration
Usage
Comparison to CABG
Symptom onset and time to intervention
Chapter 4 Bivalirudin Vs Unfractionated Heparin
Aspirin
Clopidogrel
Prasugrel and ticagrelor
Glycoprotein Ⅱb/Ⅲa-inhibitors
Heparin and bivalirudin
Heparin
Bivalirudin
Biochemistry
Pharmacokinetics
Toxicology
Clinical application of bivalirudin
Chapter 5 Methodology
Patient selection
Study protocol
Study endpoints
Statistical analysis
Results
Clinical outcomes
Chapter 7 Discussion
Comparison of abeiximab complications with hirulog for ischemia events trial(CACHET)
Randomized evaluation of PCI linking angiomax to reduce clinical events [REPLACE]-1 trial
The randomized evaluation in PCI linking angiomax to reduced clinical events (REPLACE)-trial
Safely and tolerability
Antibivalirudin antibodies and allergic reactions
Limitations of study
Conclusion
REFERENCES
Acknowledgements
List of publications
山东大学;